Lercanidipine Actavis (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels on vascular smooth‑muscle cells. This inhibition reduces calcium entry, causing the muscles to relax, which widens blood vessels (vasodilation) and leads to a decrease in peripheral vascular resistance and blood pressure.

The appropriate dose of Lercanidipine Actavis is determined by the prescribing healthcare professional based on the individual’s blood pressure, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Lercanidipine Actavis in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lercanidipine belongs to the dihydropyridine calcium‑channel blocker class, offering once‑daily dosing and a favorable side‑effect profile compared with some older agents. It provides effective blood‑pressure control with fewer reflex tachycardia episodes than non‑dihydropyridine calcium blockers, and it can be combined with other antihypertensives for synergistic effect.

Lercanidipine Actavis tablets should be stored at room temperature, below 25 °C, in the original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

Lercanidipine Actavis is taken orally, usually once daily with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.

Serious adverse reactions, though rare, can include severe hypotension, myocardial infarction, angioedema, significant liver injury, and anaphylactic reactions. Patients should seek immediate medical attention if they experience symptoms such as sudden dizziness, chest pain, swelling of the face or throat, or signs of liver dysfunction.

Lercanidipine Actavis is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation. Caution is advised for individuals with severe hepatic impairment, unstable angina, or those taking strong CYP3A4 inhibitors, unless a prescriber determines the benefits outweigh the risks.